Compare Devon Energy Corp (DVN) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs IDEXX Laboratories, Inc. — how do they compare? Devon Energy Corp trades at $48.26 (market cap $53.81B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: Devon Energy Corp is the larger of the two by market cap, and Devon Energy Corp pays a 2.62% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Devon Energy Corp for 136 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| DVN | IDXX | |
|---|---|---|
Market Cap | $53.81B | $40.43B |
Volume | 11,556,740 | 692,164 |
Sector | Energy | Health |
52-Week High | $52.07 | $766.68 |
52-Week Low | $31.74 | $504.70 |
Typical Hold Time | 136 Days | 46 Days |
Enterprise Value | $64.55B | $41.32B |
Dividend Yield | 2.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $48.92, up 2.17% today, with a bullish technical outlook and strong analyst support. Recent earnings show mixed quarterly beats, while full-year 2025 revenue of $17.19 billion and net income of $2.64 billion reflect solid profitability. Positive sentiment is driven by activist investor pressure for strategic alternatives and potential asset sales, alongside a consensus price target of $62.53 implying significant upside.
The stock presents a compelling value opportunity with a P/E of 10.63 and robust cash flow, though risks include oil price volatility and execution of asset divestitures. Wall Street's 71.9% buy rating underscores confidence in management's ability to unlock value, positioning DVN for potential gains if operational targets are met.
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
